Wednesday, June 3, 2020

Lupin inks distribution pact with 3 firms to commercialise NaMuscla in Europe

Exeltis Healthcare SL, Cresco Pharma BV and Macure Pharma ApS will
commercialise NaMuscla for the symptomatic treatment of myotonia in
adults with non-dystrophic myotonic (NDM) disorders in certain
European Union (EU) territories, Lupin said in a statement.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-inks-distribution-pact-with-3-firms-to-commercialise-namuscla-in-europe/articleshow/76171829.cms
Posted by at

2 comments:

  1. SadhanaJune 3, 2020 at 4:25 AM

    Good Article. Thanks for sharing such greatful information.
    stocks in the news
    V Guard
    Kotak Mahindra Bank
    Interglobe Aviation

    ReplyDelete
  2. Sadhana sAugust 7, 2020 at 6:26 AM

    The great thing about this post is quality information. I always like to read amazingly useful and quality content. Your article is amazing, thank you for sharing this article.
    Forex Trading
    Forex Market
    Foreign Exchange Market

    ReplyDelete

Subscribe to: Post Comments (Atom)